Skip to main content

Table 3 Vaccine characteristics influencing vaccination acceptance by demographics (N = 19,702)

From: COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries

 

Required doses of COVID-19 vaccinea

Effectiveness threshold of COVID-19 vaccineb

Adverse reactions of COVID-19 vaccinec

Duration of COVID-19 vaccine protectiond

Technology used in COVID-19 vaccinee

Producing country of COVID-19 vaccinef

Weighted

OR (95% CI)

Weighted

OR (95% CI)

Weighted

OR (95% CI)

Weighted

OR (95% CI)

Weighted

OR (95% CI)

Weighted

OR (95% CI)

Socio demography

 Age group, years

  18–29

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

  30–39

1.63 (1.41–1.87)***

0.72 (0.63–0.83)***

0.58 (0.49–0.68)***

1.01 (0.88–1.16)

1.60 (1.03–2.47)

0.99 (0.85–1.14)

  40–49

1.89 (1.61–2.22)***

0.53 (0.45–0.62)***

0.45 (0.38–0.54)***

0.99 (0.85–1.16)

2.29 (1.4–3.75)***

0.91 (0.78–1.06)

  50–59

1.91 (1.59–2.28)***

0.61 (0.51–0.73)***

0.41 (0.34–0.51)***

0.98 (0.82–1.17)

2.55 (1.52–4.29)***

0.81 (0.75–1.06)

  60 and above

1.14 (0.93–1.387)

0.69 (0.56–0.84)***

0.41 (0.33–0.51)***

1.01 (0.84–1.22)

1.26 (0.71–2.26)*

0.84 (0.69–1.02)

 Gender

  Male

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

  Female

0.86 (0.78–0.96)**

1.12 (1.01–1.25)*

1.09 (0.97–1.23)

1.07 (0.96–1.19)

1.31 (1.08–1.57)***

1.08 (0.97–1.21)

 Highest education level

  Secondary school and below

1.54 (1.27–1.85)**

1.37 (1.12–1.68)***

1.04 (0.83–1.31)

1.33 (1.10–1.61)***

0.79 (0.45–1.38)

1.08 (0.90–1.30)

  Certificate/A-Level/Diploma

1.42 (1.21–1.66)***

0.78 (0.66–0.91)***

0.58 (0.49–0.69)***

0.91 (0.77–1.06)

1.00 (0.64–1.59)

1.04 (0.89–1.21)

  Bachelor degree

1.20 (1.04–1.38)***

0.99 (0.86–1.15)

0.86 (0.73–1.01)

1.04 (0.91–1.20)

0.78 (0.49–1.25)

0.84 (0.73–0.97)*

  Postgraduate degree

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 Ever delayed acceptance or refuse vaccine despite availability of vaccine service

  Yes

1.71 (1.49–1.96)***

1.77 (1.52–2.07)***

1.82 (1.52–2.16)***

1.52 (1.32–1.75)***

1.284(0.783–2.107)

0.63 (0.55–0.73)***

  No

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

  1. Other gender was excluded due to small sample size
  2. a: Only accept single dose vs Do not mind, b: Only accept 90% threshold vs Do not mind, c: Only accept minor adverse reactions vs Do not mind moderate adverse reactions, d: Only accept lesser than 12 months vs Do not mind moderate adverse reactions, e: Do not accept mRNA technology vs Do not know much about mRNA technology/Do not mind, f: Only accept a vaccine that is produced by specific countries vs Producing countries of a COVID-19 vaccine is not of my concern in vaccine choice
  3. aP-value: P < 0.001; Nagelkerke R2: 0.044
  4. bP-value: P < 0.001; Nagelkerke R2: 0.044
  5. cP-value: 0.001; Nagelkerke R2: 0.066
  6. dP-value: 0.001; Nagelkerke R2: 0.013
  7. eP-value: 0.001; Nagelkerke R2: 0.013
  8. fP-value: 0.010; Nagelkerke R2: 0.014
  9. *P < 0.05, **P < <0.01, ***P < <0.001